Chinese Biotechnology Company Unveils Landmark Regenerative Aesthetic Medicine Innovation

Shanghai Moyom Biotechnology Co., Ltd. Announced the introduction of its new regenerative aesthetic product, Aphranel MagiCCrystal CaHA Filler, at an international event held at the Grand Halls on Shanghai’s Bund Themed “APHRANEL: Code Breaker, World Maker.” 

Aphranel MagiCCrystal CaHA Filler is the first injectable calcium hydroxylapatite (CaHA) microsphere-based dermal filler developed in China to receive NMPA Class III medical device certification, according to the press release. The product is formulated through proprietary manufacturing processes designed to control particle size, porosity, and degradation rate. Its ACD-MTTM “raspberry-like” microsphere morphology and PDC-ETTTM physically crosslinked gel matrix are intended to support safety, structural performance, and tissue integration, the manufacturer said.

In addition to national certification, the product has received EU Medical Device certification, MDSAP compliance, and regulator clearance from Mexico’s COFEPRIS, allowing market entry in Asia, Europe, and Latin America.

In the press release, Lin Guangming, chairman of Moyom Biotechnology, talked about the company’s decade of research and development, noting its work is rooted in “restoring the medical essence of aesthetic treatments."

According to a press release, the launch welcomed policymakers, industry experts, and clinicians from around the world. 

Opening remarks at the launch event were delivered by Ren Dawei, Deputy Director of the Shanghai Center of Biomedicine Development. The scientific program included keynote lectures from leading figures in plastic and aesthetic surgery, among them Professor Qi Zuoliang, Professor Cui Haiyan, Professor Luo Shengkang, Professor Chen Guangyu, Professor Li Ya, and Dr. Stefan Lipp.